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Abstract
The International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) is the premier global scientific
symposium dedicated to the exchange, advancement and dissemination of the latest research on the
pneumococcus, one of the world’s deadliest bacterial pathogens. Since the first ISPPD was held in 1998, substantial
progress has been made to control pneumococcal disease, for instance, more than half of surviving infants (78.6
million) from 143 countries now have access to the life-saving pneumococcal conjugate vaccine (PCV). The
11th ISPPD (ISPPD-11) was held in Melbourne, Australia in April 2018 and the proceedings of the symposium are
captured in this report.
Twenty years on from the first ISPPD, there remain many challenges and unanswered questions such as the
continued disparity in disease incidence in Indigenous populations, the slow roll-out of PCV in some regions such
as Asia, the persisting burden of disease in adults, serotype replacement and diagnosis of pneumococcal
pneumonia. ISPPD-11 also put the spotlight on cutting-edge science including metagenomic, transcriptomic,
microscopy, medical imaging and mathematical modelling approaches. ISPPD-11 was highly diverse, bringing
together 1184 delegates from 86 countries, representing various fields including academia, primary healthcare,
pharmaceuticals, biotechnology, policymakers and public health.
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Background
Streptococcus pneumoniae (the pneumococcus) is a ver-
satile pathogen that causes mucosal infections such as
otitis media as well as life-threatening infections includ-
ing pneumonia and meningitis [1].
The first International Symposium on Pneumococci
and Pneumococcal Diseases (ISPPD-1) was convened in
1998, a time when there was no licensed pneumococcal
vaccine for infants, who bear the brunt of invasive
pneumococcal disease (IPD). The 7-valent pneumococ-
cal conjugate vaccine (PCV) was licensed and introduced
in 2000, markedly reducing the incidence of IPD caused
by vaccine serotypes [2–4]. In 2000, an estimated 14.5
million total illnesses and 735,000 childhood deaths were
attributed to the pneumococcus [5], which placed this
Gram positive bacterium among the most important
killers of children under 5 years of age. As of 2018, the
10-valent (PCV10) and 13-valent (PCV13) formulations
of PCV had replaced the 7-valent version in 2011 and
have now been introduced in 143 countries globally,
with 58% (78.6 million) of infants having access to these
life-saving vaccines [6]. Between 2000 and 2015, there
was an estimated 51% decline in pneumococcal deaths
among children less than 5 years old [7].
Although substantial progress has been made to con-
trol pneumococcal disease, there remain many chal-
lenges and unanswered questions to be addressed. These
were the foci of the 11th ISPPD (ISPPD-11), that was
held in Melbourne, Australia from April 15th to 19th
2018. Areas of focus were; access to PCVs, continued
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disparity in disease incidence in Indigenous populations,
burden of disease in adults and serotype replacement.
Appropriately, the program for ISPPD-11 put the spotlight
on Indigenous communities in the region and around the
globe who still face unacceptably high rates of IPD, other
pneumococcal diseases and their sequelae. For example,
the slow roll-out of PCV in some regions such as Asia and
the high burden of IPD in adults where PCV impact has
been modest in some regions [8]. ISPPD-11 also brought
the very latest scientific innovations in the field including
in metagenomics, transcriptomics, microscopy, medical
imaging and mathematical modelling. The abstracts are
available online at https://isppd.kenes.com/2018/Docu-
ments/ISPPD-11%20Abstract%20Book.pdf.
ISPPD-11 brought together 1184 delegates from 86 coun-
tries, representing various fields including academia, primary
healthcare, pharmaceuticals, biotechnology, policymakers
and public health. A record high 184 delegates from 51
countries were awarded travel fellowships to support their at-
tendance, representing 16% of the delegates at ISPPD-11.
Below we describe the key highlights from the plenary
and parallel sessions.
Pneumococcal disease: the young, the old and the
vulnerable
Infants
Infancy is a time of vulnerability for pneumococcal acquisi-
tion, carriage and disease. Presentations on infant disease
focused on how early life acquisition of pneumococci, and
other factors such as malnutrition, increase susceptibility to
disease and risk of death. Another area of emphasis was the
optimal dosing schedules to sustain PCV immunization
programs, with emphasis on GAVI graduating countries.
Innovative mathematical modelling demonstrated how
early infections increased otitis media “proneness” [9]. Simi-
larly, lower respiratory tract infections (LRI) with onset
early in life were associated with progression to suppurative
lung disease (bronchiectasis). It is reassuring, however, that
PCV programs lessen otitis media “proneness” and delay
the timing of the first bacterial pneumonia hospitalization
in infancy among Australian Indigenous populations, hold-
ing promise for improved child health [10].
Other clinical and socio-demographic factors may in-
fluence IPD and IPD-related mortality in early life. A
landmark study involving 16,000 Kenyan children with
non-severe pneumonia showed that the most important
risk factors of death were moderate malnutrition (weight
for age) and clinically severe pallor [11].
The World Health Organization (WHO) recommends
three primary PCV doses given at 6, 10 and 14 weeks or 2,
4 and 6months of age. Alternatively, two primary doses
plus a booster given between the age of 9 and 15months is
also recommended [12]. There is interest in understanding
the optimal number of PCV doses and the timing of the
doses [13] while balancing cost and program sustainability.
The potential benefits of a booster-containing regimen are
being evaluated in many studies in low- and middle-
income countries (LMIC) and results from Nepal and
Vietnam are highlighted here. A study of 2 different 2 + 1
PCV10 schedules in Nepal (either 6, 14 weeks plus a booster
prior to 1 year or 6, 10 weeks plus a booster dose given be-
fore 1 year of age, produced comparable antibody responses
in Nepali infants following the booster, although antibody
levels after the primary series were lower in the 6 + 10week
age groups [14]. Comparison of a PCV10 3-dose primary
series (2, 3, 4months) was found to produce slightly higher
serotype specific antibody concentrations than a 2-dose pri-
mary schedule (2 and 4months). However, following a
booster given at 9months, the 2 + 1 schedule produced sig-
nificantly higher antibody levels, potentially demonstrating
an advantage of the 2 + 1 schedule in this setting [15].
When comparing PCV13 and PCV10 using the 2 + 1
schedule, PCV13 produced higher antibody titers than
PCV10 for most serotypes post-primary series, while similar
levels were seen for both vaccines at 9months pre-booster
and following the booster [15].
In Malawi, administration of PCV13 as a 3 + 0 schedule
demonstrated good infant protection against IPD, with herd
(indirect) effects demonstrated in older children [16]. Key to
the optimal dosing issue is the need for high coverage. For
example, Nigeria, Africa’s most populous country, has PCV
coverage below 30% despite the pneumococcus being the
most common cause of meningitis [17]. The data presented
suggested that with adequate coverage, PCV10 could have
prevented 50% of cases of pneumococcal meningitis in Ni-
gerian children under five years reported between 2010 and
2016 [17]. An action plan is needed to ensure high vaccine
coverage in high-mortality regions.
Although the infant vaccination programs have been
largely successful, protection of newborns against
pneumococcal disease remains a challenge in some re-
gions. Although the mechanisms are poorly understood,
experiments in neonatal mice suggest that T-helper cell
activation may be impaired in newborns [18]. Maternal
vaccination may provide protection during the neonatal
period, a strategy that has been implemented success-
fully against diseases such as pertussis and tetanus [19].
However, there are concerns that maternal antibodies
may interfere with subsequent immune responses fol-
lowing administration of PCV among infants.
Definitive data on the safety and effectiveness of PCV
maternal vaccination is required as is the need for en-
hanced understanding of the burden of disease in very
young infants and key differences to that of older in-
fants. As the jury is still out on the optimal PCV dosing
and scheduling, it is important to note that there may
not be a “one-size fits all” strategy for all countries and
populations.
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Adults
Among the elderly, community acquired pneumonia
(CAP) is the most common type of pneumococcal disease.
The dominant presentation of pneumococcal CAP is non-
bacteraemic/non-invasive disease while invasive infections
involving normally sterile sites occur in a quarter of cases
[20]. Vaccines which contain purified capsular polysaccha-
rides (PPVs) are effective against invasive disease in adults
but their efficacy against non-invasive pneumonia remains
controversial [21, 22]. It is also unclear how PPV protec-
tion against disease and carriage wanes over time in adults
[22]. At ISPPD-11, there was a focus on protection of
adults and innovations for timely diagnosis of CAP.
Japan has experienced an increase in uptake of the 23-
valent polysaccharide vaccine (23vPPV) among the elderly
following the 2011 tsunami. The free pneumococcal vacci-
nations offered to tsunami victims >65 years may have
contributed to the increased uptake [23]. Suzuki and col-
leagues [24] found that effectiveness of 23vPPV against
pneumococcal pneumonia was 27% but wanes over time
and with increasing age at vaccination. Macintyre and col-
leagues conducted a randomized control trial (RCT)
among hospitalized elderly Australians who were recruited
to receive either 23vPPV alone or PCV7 and 23vPPV [25].
They found substantial waning of immunity between 12
and 60 months post vaccination for all serotypes using the
opsonophagocytic assay (OPA). The clinical implications
of this waning immunity remain unclear.
An alternative to 23vPPV is PCV vaccination among
adults. The Community-acquired Pneumonia Immunization
Trial in Adults (CAPITA) [26] study conducted in the
Netherlands showed that the vaccine efficacy of PCV13
among adults >65 years was 45.6% (95% CI: 21.8–62.5) for
the first episode of vaccine-type CAP. The efficacy for non-
invasive CAP was much lower 45.0% (95% CI: 14.2–65.3)
compared to invasive CAP 75.0% (95% CI: 41.4–90.8). At
ISPPD-11, Gessner and colleagues [27] presented findings
from a post hoc analysis of The CAPITA study. Vaccine effi-
cacy for all hospitalized pneumonia was comparable for clin-
ical pneumonia 8.1% (95% CI: − 0.6-16.1) and adjudicated
(clinical plus radiological) pneumonia 6.7% (95% CI: 4.1–
16.23). Vaccine efficacy was highest against hospital episodes
for vaccine type IPD 75.8% (95% CI: 47.6–98.8) and IPD
49.3% (95% CI: 23.2–66.5). Together, these findings support
that PCV13 is effective in preventing both invasive and non-
invasive vaccine-type CAP. Questions remain regarding the
cost effectiveness of rolling out PCV13 for adults with exist-
ing immunization programs [28]. The final decisions will
largely depend on the herd immunity conferred by infant
immunization programs and the lower cost of 23vPPV com-
pared to PCV13. For example, in 2019, the Advisory Com-
mittee on Immunization Practices (ACIP) downgraded the
universal recommendation for PCV13 use for adults
>65years and decisions to administer PCV13 will now be
based on shared clinical decision-making. The updated rec-
ommendation was supported by the finding that herd im-
munity from PCV13 infant immunizations made a more
significant impact than vaccinating adults in the US [29].
Although a significant proportion of pneumococcal
pneumonia remains undiagnosed, surveillance for inva-
sive pneumococcal disease provides indirect data on
serotype distribution and the changing incidence of non-
invasive disease. Data on CAP incidence among adults
in Sub-Saharan Africa are scant, but the incidence of
pneumococcal pneumonia is known to be very high in
people with human immunodeficiency virus (HIV) infec-
tion [30]. In South Africa, the highest incidence of IPD
was reported in adults 25–44 years, the age group with
the highest HIV prevalence [31]. Seven years after the
introduction of PCV in South Africa, IPD rates had de-
clined by 45% (95% CI: 43 − 48%) in adults >25 years of
age, despite some replacement disease. In contrast
with many high income countries, routine pediatric vac-
cination in South Africa appears to have had little indir-
ect impact on IPD in older adults ≥65 years of age.
The global burden of IPD will likely grow with the
increasing ageing population and replacement of
vaccine-serotypes [32]. There is a need to focus re-
search on the most effective vaccine strategies to pro-
tect the elderly from IPD and pneumonia. In addition
to HIV prevention/treatment, other measures to re-
duce IPD include approaches to reduce uptake of
cigarette smoking and indoor air pollution from cook-
ing, as well as optimize herd protection from child-
hood pneumococcal vaccination.
Indigenous populations world-wide
Issues of Indigenous health took center stage at ISPPD-
11. Indigenous communities deserve the spotlight for
their role in research that led to watershed advances in
vaccinology and pneumococcal epidemiology. Despite
the high effectiveness of PCVs in Indigenous popula-
tions, particularly in reducing the burden of vaccine-type
IPD, data presented from Australia and the United
States of America (USA) highlight the ongoing pneumo-
coccal disease disparity between Indigenous populations
and the general population.
Data from Australia’s National Notifiable Disease Sur-
veillance System showed that IPD remains a significant
health burden in Australian Indigenous populations [33].
The disparity between Indigenous and non-Indigenous
Australians is actually increasing and is most pronounced
in young adults. Similarly, in the USA, the residual burden
of IPD on the Navajo Nation is higher than the general
population [34]. These differences in populations must be
taken into account when assessing research questions and
policy issues, such as optimal dosing schedules [35].
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Additionally, other aspects pertinent to Indigenous popula-
tions, especially in Aboriginal and Torres Strait Islander
communities across Australia, were highlighted by Australia’s
first Indigenous Ear Nose and Throat (ENT) surgeon, Dr.
Kelvin Kong. He challenged delegates at ISPPD-11 to think
beyond the pneumococcus and to look beyond vaccines [36],
emphasizing the unacceptable toll that otitis media – and its
sequelae – continues to exert in Aboriginal and Torres Strait
Islander communities across Australia, resulting in social iso-
lation, poor educational outcomes and lost opportunities. He
called out the pervasive racism that continues to create bar-
riers to care-seeking, preventing appropriate recognition and
treatment of disease, and called for community-driven,
culturally-appropriate, locally-delivered solutions that reflect
the social reality of Aboriginal and Torres Strait Islander
communities.
Five clear priorities were identified for the reduction in
disease in Indigenous populations: 1) maximizing vac-
cine coverage, 2) ensuring policy-relevant data collec-
tion, 3) optimizing dosing products and schedules, 4)
evaluating new vaccines with broader serotype protec-
tion, and 5) addressing the social determinants of health
that underlie the high burden of pneumococcal disease.
Epidemics, outbreaks and emergency settings
Optimal vaccination strategies are a priority for humani-
tarian emergencies, which affect 150–200 million refugees
and internally displaced persons annually [37]. People liv-
ing in overcrowded places such as refugee camps and
other poor living conditions are at risk of pneumococcal
outbreaks [38–42]. In all refugee communities, pneumo-
nia continues to be an important cause of illness and
death. The Humanitarian Mechanism, launched in 2017,
represents an important initiative providing access to
PCVs and potentially other vaccines at GAVI prices [43].
The message was clear at ISPPD-11, we need vaccin-
ation programs that are feasible, provide rapid protec-
tion, maintain immunity over a protracted phase, are
cost-effective, and minimize opportunity costs through
integration with other health services [44]. Mathematical
modelling approaches can be applied to determine the
optimal strategy, cost-effectiveness, and need for use of
PCV in humanitarian settings [45].
In Sub-Saharan Africa’s “meningitis belt” which spans
from Senegal to Ethiopia, there are seasonal meningitis
outbreaks, primarily caused by Neisseria meningitidis but
including many cases caused by pneumococci. Outbreaks
of pneumococcal meningitis continue to pose a significant
public health threat along Africa’s meningitis belt.
Kwambana-Adams outlined how pneumococcal meningi-
tis outbreaks peak during the dry and dusty season, and
are characterized by high rates of mortality and serious se-
quelae in survivors [46]. Serotype 1 dominates, but menin-
gitis cases are also being caused by other pneumococcal
serotypes. There has been a shift in the age distribution of
meningitis cases following PCV introduction, from pri-
marily children under 5 years to a predominance in older
children and adults [46, 47]. Notably, in the Gambia the
serotype 1 carriage reservoir is likely to be in the 5–14 year
age group [48]. Other pneumococcal IPD outbreaks were
reported among the homeless in Canada, attributed to
two serotype 4 genotypes and in Israel related to a unique
clone of serotype 2 [49].
Infant vaccination programs alone may not be sufficient
to protect the vulnerable populations against IPD out-
breaks across the globe. Optimal population-specific vac-
cination strategies targeting outbreak control are needed.
Additionally, preparation for future outbreaks in Africa as
well as the Asia-Pacific region requires strengthened sur-
veillance [50].
Diagnosis and treatment
Timely diagnosis and the correct assessment of pneumococcal
disease remains an immense challenge, even in high-resource
settings [32], and may result in delayed or suboptimal treat-
ment of patients and underestimation of the burden of dis-
ease. The new innovations presented at ISPPD-11, ranging
from computer-aided platforms, low-cost pulse oximeters and
diagnostics based on non-invasive clinical specimens, may
revolutionize pneumococcal disease diagnostics. Tools that are
accessible and can be used in low-resource settings are par-
ticularly promising.
Several presentations focused on the need for im-
proved diagnosis of pneumonia in children, three of
which are highlighted here. Discordance between the
WHO clinical case definition of pneumonia and radio-
graphic diagnosis (based on WHO criteria) was reported
in a study from Nepal [51] where two-fifths of those
with radiological pneumonia did not meet WHO clinical
criteria, mostly due to a lack of tachypnoea. This dis-
cordance does not infer “incorrect” diagnosis, but rather
highlights the limitations of different diagnostic stan-
dards and the importance of considering these limita-
tions in research and practice. Mahomed and colleagues
[52] presented a computer aided diagnostic algorithm
for chest X-ray (CXR) interpretation for childhood
pneumonia. Using expanded data from the Pneumonia
Etiology Research for Child Health (PERCH) study
South African site, the algorithm had 70% sensitivity and
72% specificity (compared to expert radiology opinion).
Given the challenges of interpretation of CXRs in chil-
dren this is promising, especially as there is capacity to
further improve the diagnostic algorithm.
Improvement in measurement of hypoxemia in chil-
dren was described by Boyd and colleagues [53]. They
have developed a novel pediatric pulse oximetry probe
and demonstrated both high quality and reuseability by
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both expert clinicians and health workers in Malawi,
Bangladesh and the United Kingdom.
Non-invasive pneumococcal disease diagnostic tools for
adults were presented. One study found that sputum PCR
was more sensitive overall and better at detecting non-
systemic pneumococcal pneumonia than urine antigen de-
tection [54]. Although still requiring further validation, a
new 24-valent serotype-specific urinary antigen test in adults
enhanced diagnosis of pneumococcal pneumonia [55].
Minimally invasive post-mortem tissue sampling to de-
termine cause of death, was also discussed at ISPPD-11,
and may shed more light on the true burden of IPD in
children in LMIC settings [56].
New treatment strategies for otitis media were also
discussed. Using a chinchilla model, Sabharwal and col-
leagues [57] demonstrated that local administration of
gemifloxacin-containing gel cleared pneumococcal acute
otitis media in most (13/14) animals. They found that
use of 4% ciprofloxacin and 1% gemifloxacin gel quickly
sterilized the ear (90% within 5 h) with negligible sys-
temic absorption and superior efficacy to no treatment
or oral comparison treatments [57].
Weighing the balance: vaccine impact and serotype
replacement
Under the pressure of pneumococcal vaccines, pneumococ-
cal epidemiology continues to evolve [58]. At ISPPD-11 the
increasingly diverse impacts of PCVs on pneumococcal dis-
ease were presented. One of the most illustrative examples
of impact differences is that of serotype replacement.
Lessa and colleagues [47] used inpatient data from 23
US states collected between 2005 and 2014 to determine
the rates of all cause pneumonia (ACP), non-invasive
lobar pneumonia (10th edition of the International Clas-
sification of Diseases (ICD10)-coded) and IPD. This
study including 83.4 and 78.8 million hospitalizations
pre and post PCV13 introduction respectively, showed
reductions in lobar pneumonia hospitalizations. Ap-
proximately 23,674 (Credible Interval: 12,637 - 38,484)
hospitalizations across all ages have been averted be-
tween 2010 and 2014, post PCV13 introduction on a 3 +
1 schedule. Declines in ACP were only observed among
children <5 years but not among older children and
adults. The decline in IPD hospitalizations were very
modest across all age groups, the largest decrease of
1574 (Credible Interval: 907–3907) was found among
those <18 years [47].
The Active Bacterial Core surveillance (ABCs) showed
declines in overall and PCV13 IPD of 61% and 87% re-
spectively among North American children <5 years fol-
lowing introduction of PCV13 [59]. Similar trends were
observed among older age groups. Serotype replacement
appears not to be a major problem in the USA, at this
time [60].
Studies from other regions are sharply contrasted with the
USA where pneumococcal disease caused by non-PCV13 se-
rotypes is a major concern. European Streptococcus pneumo-
niae Invasive Disease Network (SpIDnet) includes 10
European countries with varying infant immunization sched-
ules and PCV formulations. SpIDnet demonstrated an even
more dramatic 84% increase in non-PCV serotypes following
PCV implementation across Europe [61]. The United King-
dom (UK) has seen declines in IPD and PCV13-type IPD, off-
set by significant increases in non-PCV13 serotypes,
particularly since 2013 [62]. The incidence of IPD caused by
non-PCV13 serotype IPD has doubled, with serotypes 8, 12F
and 9N responsible for > 40% of IPD cases in 2016/17. Nearly
complete replacement disease has been observed in adults in
the UK. Another interesting aspect of replacement in the UK
is that early replacement was largely due to serotypes with a
low case:carrier ratio prior to PCV13 introduction. However,
the replacement under the pressure of PCV13 has been dif-
ferent, characterized more by serotypes with a greater case:
carrier ratio. In South Africa, non-PCV13 serotypes increased
by nearly a third, with serotypes 8 and 35B being the domin-
ant serotypes following PCV13 implementation [27].
In a recent article, Lewnard and Hanage [63] explored
potential factors that may account for the observed dif-
ferences on the impact of PCV13 on disease caused by
non-vaccine serotypes in the USA, UK and Europe.
These include surveillance practices, population risk fac-
tors, transmission dynamics and pathogen evolution.
England and Wales have experienced a large increase
in IPD in adults >45 years post PCV13 introduction in
2010, with 8, 9N, 12F and 15A being among the most
notable non-vaccine serotypes [62].
Senghore and colleagues provided insights into vaccine sero-
type persistence in the Gambia, a setting with a 3+0 PCV13
schedule [64]. Transmission of serotype 1, the predominant
serotype, was ongoing five years after PCV13 introduction
coupled with clonal expansion of non-PCV13 serotypes.
Mungall and colleagues [65] questioned the dogma,
through a systematic review of published literature, that the
impact of PCV on IPD correlates with the impact on naso-
pharyngeal carriage. Although there was good correlation
when all the serotypes were grouped into vaccine and non-
vaccine types, the correlation was poor at the level of indi-
vidual serotype, which warrants further investigation.
Overall, pneumococcal ecology continues to evolve
with serotype replacement being observed in most, but
not all, countries. Further investigation to understand
the biological basis for serotype persistence and selection
are required to inform development of future vaccines
and vaccine programs.
Vaccine studies from the Asia-Pacific
Despite having a large share of the global burden of
pneumococcal disease, the Asia-Pacific region has lagged
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behind the rest of the world in the introduction of PCVs.
Currently, countries that have introduced PCVs are
evaluating impact, especially for pneumonia where vac-
cine type pneumococcal carriage among pneumonia ad-
missions and/or among children in the community is
being assessed.
In 2012, Fiji became one of the first countries in the
region to introduce PCV. A comprehensive evaluation of
PCV10 impact showed significant reductions in severe
pneumonia (35%), hypoxic pneumonia (35%) and radio-
logical pneumonia (28%) among children 2–23months
of age following PCV introduction with variable reduc-
tions in all cause pneumonia in the different age groups
[66]. Nepal introduced PCV13 in a novel 2 + 1 schedule
(6 weeks, 10 weeks and 9months) in 2015 [67]. Signifi-
cant decreases in vaccine-type carriage in pneumonia
patients were observed in children <2 years of age.
Some countries in the region have elected to introduce
PCV in a phased manner. In India, PCV13 introduction
started in 2017 focusing on the five states with high
child mortality (Uttar Pradesh, Bihar, Madhya Pradesh,
Rajastan and Himachel Pradesh) reaching over 2 million
children. Evaluation of IPD, pneumonia and NP carriage
in pneumonia patients is ongoing. In Himachal, PCV13
is currently being used but in the coming years Indian
manufacturers will likely enter the market with new
PCV formulations [68]. In Mongolia, PCV13 introduc-
tion began in the capital, Ulaanbaatar, in 2016. The
introduction was undertaken in a phased manner to fa-
cilitate evaluation of the impact on pneumonia admis-
sions. As part of that impact evaluation, nasopharyngeal
carriage is being monitored among children admitted to
hospital with pneumonia [69].
Early evidence from countries leading the way in the
region presented in this session provided much needed
data to advocate for roll-out of PCVs throughout the re-
gion. In addition to introduction and measurement of
impact, vaccine development is ongoing in India. Devel-
opment of new PCVs by Indian manufacturers will in-
crease the availability and reduce the cost of PCVs that
may lead to increase usage of PCV in LMICs where PCV
introduction is still lagging. Lower-cost PCVs may also
ensure the sustainability of PCV among countries that
graduate from GAVI support.
Epidemiology and mathematical modelling
While PCVs have been in use for nearly twenty years,
there is still much to learn about how pneumococci
change in response to vaccination, and what the implica-
tions are of different vaccination strategies. There is also
a need for non-inferior, low cost PCV formulations and/
or alternate dose schedules that help sustainability for
infant PCV programs. At ISPPD-11, presenters described
classical observational epidemiology and mathematical
modelling approaches to address these issues.
Croucher and colleagues [70] presented work that syn-
thesizes pneumococcal population structure to identify
drivers of vaccine-driven strain selection in disparate popu-
lations. This type of interdisciplinary approach represents
the cutting-edge of the field and could be used to tailor op-
timal vaccine formulations in different populations.
Ojal and colleagues [71] used dynamic transmission
models and economic analyses to show that continuing
PCV will prevent 15,355 deaths in Kenya between 2022
and 2032 at a cost of USD 15.6 million annually. Thus,
continued PCV use will be cost effective for the country.
This study from Kenya is important for understanding
the potential impacts of PCVs in low income settings
and for decision-making. Sbarra and colleagues [72] pre-
sented a modeling framework for synthesizing estimates
of PCV impact between countries, for evaluating vari-
ables associated with higher or lower impact, and for
obtaining estimates of impact where the quality of local
data is poor. This could aid in efforts to understand vari-
ability in PCV impact between settings and the evalu-
ation of different dosing schedules.
To address the issue of optimal PCV dose scheduling,
Choi and colleagues [73] used a dynamic transmission
model to show that switching from a 2 + 1 to 1 + 1 PCV
schedule in the UK would result in a modest increase in
vaccine type carriage and IPD among infants. They pro-
posed that the strong herd immunity established in this
population would counter the effects of reduced doses.
Although controversial, this work has important implica-
tions for ongoing policy discussions surrounding the in-
tricate balance between cost savings and pneumococcal
disease prevention.
Together, these studies demonstrate the importance of
modelling in evaluating the impact of PCVs in a variety
of settings and address ongoing challenges for policy,
vaccine design and schedule optimization.
New vaccines and new trials
Although having registered remarkable success, currently
licensed pneumococcal conjugate and polysaccharide vac-
cines have limited valency, providing protection against a
small proportion of nearly 100 known pneumococcal se-
rotypes. PCV success is threatened by the ever-looming
possibility of non-vaccine type replacement disease.
The progress on the development of PCVs with broader
valency, PCV15 [74] and PCV24 [75] as well as a lower
cost PCV10 from the Serum Institute of India [76], were
discussed. Stacey and colleagues demonstrated that two
different preparations of PCV15 both have safety profiles
comparable with that of PCV13 [77]. Both PCV15 formu-
lations (PCV13 serotypes plus 22F and 33F) induced
serotype-specific antibody responses to all 15 serotypes in
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the vaccine, and these responses were non-inferior to
PCV13 for common serotypes, measured both by
serotype-specific opsonophagocytic activity (OPA) and
IgG geometric mean titers (GMCs). The challenge re-
mains as to how many additional serotypes can be added
while maintaining safety and immunogenicity.
There is a pressing need to develop new vaccine strat-
egies and the current focus is on protein and whole cell
vaccines [78–81]. To date the results from clinical trials
testing protein vaccines have not been promising, but
there is still a need to develop an effective pneumococcal
protein vaccine. A group based at the Papua New
Guinea Medical Research Institute with Australian col-
laborators measured antibody responses to four
pneumococcal protein vaccine candidates [82]. They
found high levels of natural antibody against these pro-
teins in early infancy, but the protective role of these
antibodies is yet to be evaluated.
A discussion by a panel of experts highlighted several
key challenges relating to vaccine development and
evaluation. There is a need for protection against a
broader breadth of serotypes, but interest in non-
capsular pneumococcal vaccines has declined while evi-
dence of the limitations of PCVs is growing stronger.
The pathway to licensure is considered a key barrier to
the development of new pneumococcal vaccines, par-
ticularly protein vaccines, as there are no known corre-
lates of protection. Thus, engagement with regulators is
needed, to develop new approaches for evaluating and li-
censing vaccines that account for potential ecological ef-
fects. Expanded valency PCVs may suffer from “GMC
creep” whereby serotype-specific IgG responses may de-
crease as more serotypes are added to the vaccine. It is
unknown when this becomes clinically significant. Add-
itional questions arise given the fact that much of the
pneumococcal disease burden resides in adults, but most
work in vaccine development is focused on pediatric
vaccines. Should we be making a different PCV for
adults targeting serotypes causing IPD in adults? Should
we be evaluating new vaccines initially in adults rather
than children?
Host and microbial interactions
Host-pathogen interactions
Fundamental to success of pneumococcal colonization
and disease is the capacity of the organism to interact with
epithelial and endothelial surfaces whilst evading host de-
fenses [83]. The complex interplay between pathogen and
host dictates tissue tropism and disease severity [84].
Speakers at ISPPD-11 demonstrated the utility of cutting-
edge sequencing technologies and microscopy tools in ad-
vancing our understanding of the mechanisms underlying
pneumococcal-host interactions.
The rapid transcriptomic reprogramming by both host
and pathogen underscores the dynamic responses that drive
successful pneumococcal colonization and facilitate invasive
disease. Veening and colleagues [85] presented exciting data
from dual RNA-seq performed in an innovative zebrafish
embryo pneumococcal meningitis model. This study showed
that S. pneumoniae strain D39 increased transcription of
competence, pyrimidine and heat shock genes in response to
interaction with brain tissue. Jhelum and colleagues [86] also
demonstrated that pneumococci have mechanisms to pack-
age DNA-degrading enzymes into vesicles, which in turn fa-
cilitates the destruction of neutrophil extracellular traps.
Two-photon microscopy demonstrated that pneumo-
coccal translocation into the central nervous system can
occur through non-hematogenous routes involving the ol-
factory system in a mouse model [87]. This is further evi-
dence of the remarkable ability of the pneumococcus to
circumvent the blood-brain barrier to cause meningitis.
Through application of super-resolution microscopy of
human meningitis samples, it was revealed that pneumo-
coccal pili interacts with two blood-brain barrier endo-
thelial receptors, polymeric immunoglobulin receptor
(pIgR) and platelet endothelial cell adhesion molecule
(PECAM-1), which in turn facilitate pathogen entry into
the brain [88]. Targeting the intimate interactions be-
tween the pneumococcus and these receptors resulted in
reduced bacterial translocation, demonstrating the po-
tential for targeting such pathways therapeutically [89].
These findings underscore the multiple, potentially re-
dundant, pathways that the pneumococcus can employ
to invade the central nervous system. Mechanistic un-
derstanding of how the pneumococcus gains access to
this highly privileged host niche can be leveraged for the
development of interventions to prevent meningitis.
Immunology
In recent years, substantial progress has been made in our
understanding of the immunological basis of protection
against pneumococcal carriage. At ISPPD-11, we gained
new insights into the complex interactions between host
immunity and the pneumococcus, particularly at the mu-
cosal surface. A number of speakers presented innovative
approaches to enhance our knowledge of novel cellular
immune responses associated with protection against
pneumococcal carriage, impact of bacterial-viral inflam-
matory responses and new approaches to vaccination that
could provide serotype-independent protection against
pneumococcal disease.
A cutting-edge proteomic study showed that exposure
to pneumococcus during the first two years of life elic-
ited antibody responses to protein variants of PspA,
PspC, ZmpA and ZmpB [90], and that vaccination with
the whole cell vaccine (WCV) produced similarly con-
sistent responses to functionally diverse proteins [91].
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Intranasal vaccination in mice with conserved lipopro-
teins such as DacB, MetQ and PnrA was associated with
reduced bacterial loads and increased nasal IL-17A
levels. These studies offer hope that protein-based broad
protection against the pneumococcus may be achievable
in the future and support the further development of
whole-cell and protein vaccines.
A human challenge model study showed enhanced ac-
tivation of alveolar macrophages in individuals within 4
months of an episode of pneumococcal colonization.
The clearance of pneumococci in the lungs may be mod-
ulated by the activity of alveolar macrophages and en-
hanced expression of IFN-ɤ and IL-4 [92].
A study of B-cell responses to pneumococcal serotypes
following varied PCV schedules provided a new perspec-
tive on markers of long-term immunity. Examining the
predictive power of this approach as a predictor of pro-
tection against carriage in Vietnam (where there is still
no national PCV program) will be a report to look for
at ISPPD-12 [15].
Effective protection of immunocompromised individuals
against IPD remains a challenge as highlighted in previous
sections. It was found that specific adaptive immune cells
such as T follicular cells (Tfh) were important for anti-
body production in response to pneumococcal polysac-
charide vaccination [93] but that this was impaired during
HIV-infection, whereas an extra PCV13 booster could
provide additional benefit among immunocompromised
individuals [94].
In summary, significant advances continue to be made
in our understanding of novel immune correlates of pro-
tection against pneumococcal carriage and disease. These
findings will be critical in our efforts to develop broad-
based protection against this highly complex pathogen.
Interaction between pneumococci and viruses
Pneumococci co-colonize or co-infect a host together with
other pathogens, including viruses, bacteria, and/or hel-
minths [95]. There are data on influenza-pneumococcal co-
infection reviewed elsewhere [96], but epidemiological data
indicate several other pathogens are co-detected in individ-
uals with pneumococcal disease. How these alter pneumo-
coccal prevalence, carriage, susceptibility, and disease course
is not well understood. Speakers at ISPPD-11 highlighted the
mixed etiologies of pneumococcal coinfection.
In Vietnam, among children under 15 years with acute
respiratory illness, those colonized by a virus (respiratory
syncytial virus (RSV), human-metapneumovirus, rhinovirus
or adenovirus) were more likely to be co-colonized with the
pneumococcus. Children with clinical pneumonia and RSV
colonization appeared to have longer hospitalizations than
those without RSV [97]. This finding is consistent with data
reported from animal model studies of pneumococcal co-
infections with RSV [98], Trichuris muris [99], and
influenza virus [100]. Further investigation into RSV-
pneumococcal coinfection showed that inflammatory
markers and overall disease were also enhanced, but that
epithelial integrity was maintained [98]. Like influenza-
pneumococcal coinfections [96, 100–102] alveolar macro-
phages during T. muris infection exhibit reduced killing
capacity [99]. In T. muris-pneumococcal coinfection, in-
creased carriage and dissemination of pneumococci into
the lungs was also observed [99]. Pneumococcal serotypes
were found to be more diverse in mixed-infections [103].
The prevalence and mechanisms of multi-pathogen in-
fections is beginning to be better understood. The com-
plexity of these infections and the phenotypic changes
that ensue in multi-pathogen pneumococcal infections is
of high importance and should be further investigated.
This may be an important factor explaining the link be-
tween pneumococcal disease incidence and microbial
community development. The knowledge gained will un-
doubtedly aid the control of pneumococcal-related dis-
eases in future.
New frontiers in pneumococcal “omics”
Genomics and transmission
Exciting advances in genomic analyses exploring
pneumococcal virulence, antibiotic resistance and popu-
lation structure were discussed in depth at ISPPD-11.
Hiller demonstrated the significance of gene transfer in
tissue tropism, focusing on a group of strains that form a
distinct phyletic group within the pneumococcus that are
well adapted to infect the conjunctiva [104]. The surface-
exposed adhesin, SspB, is encoded exclusively by strains in
this distinct phyletic group and promotes adherence to
cultured cells from the ocular epithelium. Phylogenetic
analysis of the sspB gene suggested that it was acquired by
lateral gene transfer from Streptococcus suis.
Genomic approaches have also been used to address why
and how antibiotic resistant and sensitive pneumococcal
strains co-exist, which is hard to explain with simple
models. Lehtinen and colleagues’ work demonstrated that
duration of carriage can modulate the fitness effect of anti-
biotic resistance, whereby prolonged duration of carriage of
a serotype increases the fitness advantage gained from re-
sistance [105]. This is intuitively easy to understand, as the
longer it takes for the pneumococcus to transmit, the
greater the chance that the host will receive an antibiotic
prescription for any infection. These findings suggest that
any locus that increases the duration of carriage is linked
with the evolution of resistance to antibiotics.
While capsular serotype is known to contribute to
pneumococcal invasiveness, investigators at ISPPD-11
demonstrated that genetic lineage also contributes to inva-
siveness [106]. Clade specific clustering linked to either
carriage or invasive disease was found among serotype 1
strains from West Africa [107]. A study employing novel
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genome-wide association study (GWAS) and joint sequen-
cing approaches identified pneumococcal genes important
in meningitis that are involved in competence, metabolic
pathways and bacteriocins. Host variation in Coiled-Coil
Domain Containing 33 (CCDC33) and serine/threonine
kinase 32C (STK32C) were associated with susceptibility
to pneumococcal meningitis [108].
The impact of vaccination on the pneumococcal pan-
genome before and after the introduction of PCV in
Navajo and White Mountain Apache was investigated by
Azarian and colleagues [77]. Population genetic analyses
were consistent with a bottleneck effect following the
introduction of PCV, followed by expansion of the non-
vaccine type strains that made up the majority of the
post vaccine population.
Pneumococcal molecular microbiology
Upper respiratory tract carriage of the pneumococcus
accompanies pneumococcal disease and is the source of
host-to-host transmission. Development of molecular
tools and their application to assess the ‘pneumobiome’
of the upper respiratory tract in large cohorts has pro-
gressed significantly since the last WHO Pneumococcal
Carriage Working Group Recommendations were pub-
lished [109]. Novel approaches are being proposed with
promising results. Speakers at the ISPPD-11 revealed the
value of short read sequencing of extracted nucleic acid
from nasopharyngeal swabs to evaluate pneumococcal
antibiotic susceptibility [110] and serotype-specific car-
riage patterns [111], and the application of microarray to
assess serotype-specific pneumococcal carriage duration
and density in the first year of life [112].
Comparison of latex agglutination, whole genome se-
quencing and microarray for pneumococcal serotyping
on nucleic acid extracted from nasopharyngeal swabs re-
vealed high concordance for pneumococcal serotype
identification between the three approaches. However,
whole genome sequencing and microarray provided add-
itional resolution of non-vaccine serotype carriage, al-
though increasing the cost and the level of technical
expertise required [113].
Identification of a new PCR target (SP2020, TIGR4 no-
menclature) with 100% specificity and 99.3% positive pre-
dictive value, was revealed and suggested to be duplexed
with lytA for unequivocal identification of S. pneumoniae
[114]. Streptococcus mitis strains that express pneumococ-
cal serotype 1 capsule have been discovered in the oro-
pharynx of adults using the pneumococcal cps1 PCR
[115]. This finding has significant implications for
pneumococcal serotyping approaches.
In summary, culture-independent approaches to dir-
ectly interrogate the pneumobiome of the upper respira-
tory tract are of high value and are being actively
investigated. In the near future, thorough validation of
these approaches will likely lead to updated recommen-
dations for highly sensitive detection of pneumococci in
polymicrobial samples.
Conclusions
Twenty years on from the first ISPPD held in 1998, much
progress has been made to combat pneumococcal diseases
globally. It was clear at the meeting that pneumococcal re-
searchers are employing the best cutting-edge technolo-
gies to enhance our understanding of the pneumococcus
and to develop new strategies to prevent, diagnose and
treat pneumococcal infections.
ISPPD-11 held in 2018 gave pneumococcal researchers
an opportunity to celebrate the great strides that have
been made over two decades. In 2018, 58% of surviving
infants had access to PCVs and 51% had been vaccinated
[6].
Although there is a large burden of disease in Asia and
PCV implementation has been slow, PCV introduction
in several countries and the consequent impact, serve as
an impetus for other countries to introduce PCVs. We
acknowledge the efforts of individuals and organizations
that tirelessly advocate for PCV implementation and
roll-out. Another topical issue at ISPPD-11 was the per-
sisting large burden of pneumococcal disease among the
elderly. The European Commission estimates that people
over 65 years old will account for a third of the popula-
tion in Europe by 2050, nearly double that in 2000. Most
likely, the burden of pneumococcal disease will grow
with this population if nothing is done.
Other populations who continue to bear a dispropor-
tionate burden of disease and among whom urgent action
is needed are refugees, internally displaced persons and
the homeless. More data from refugee settings describing
the burden of pneumonia by age and nutritional status are
required. Millions of people in Africa’s meningitis belt re-
main at risk of deadly pneumococcal meningitis outbreaks
despite the introduction of PCVs. Global coordination
during crises with systematic evidence-based decision-
making on vaccination is urgently needed. These chal-
lenges underscore the need to look beyond infant
immunization programs and develop new strategies to
combat disease in high-risk populations.
ISPPD-12
ISPPD-12 will be held in Toronto, Canada from the 21st
to the 25th of June 2020. This installation of ISPPD is
set to have an innovative program bringing together
pneumococcal researchers and partners from across the
globe. More information and updates on ISPPD12 can
be found at https://lp.www2.kenes.com/isppd2020/.
Abbreviations
ACP: All cause pneumonia; CAP: Community acquired pneumonia;
CAPITA: Community-acquired Pneumonia Immunization Trial in Adults;
Kwambana-Adams et al. Pneumonia            (2020) 12:2 Page 9 of 14
CI: Confidence interval; CXR: Chest X-ray; DNA: Deoxyribonucleic acid;
ENT: Ear, Nose and Throat; GMC: Geometric mean concentration;
GSK: GlaxoSmithKline; GWAS: Genome-wide association study; HIV: Human
immunodeficiency virus; IFN: Interferon; IL: Interleukin; IPD: Invasive
pneumococcal disease; ISPPD: International Symposium on Pneumococci
and Pneumococcal Diseases; LMIC: Low- and middle-income countries;
LRI: Lower respiratory infection; NP: Nasopharyngeal; OPA: Opsonophagocytic
assay; PCR: Polymerase chain reaction; PCV: Pneumococcal conjugate
vaccine; PECAM: Platelet endothelial cell adhesion molecule;
PERCH: Pneumonia Etiology Research for Child Health; PPV: Pneumococcal
polysaccharide vaccine; RCT: Randomized control trial; RNA: Ribonucleic acid;
RSV: Respiratory syncytial virus; UK: United Kingdom; USA: United States of
America; VT: Vaccine type; WCW: Whole cell vaccine; WHO: World Health
Organization
Acknowledgements
We would like to thank the ISPPD Board Members, Australian Local
Organizing Committee and Officers. We gratefully acknowledge all of the
session Chairs, the oral and poster presenters as well as all the other
delegates who participated in ISPPD-11. The ISPPD group includes the listed
authors and: Brenda Anna Kwambana-Adams1, E. Kim Mulholland2,3,4
Catherine Satzke2,3,5 Heidi Smith-Vaughan6,7 Angela Brueggemann8,9 Cynthia
Whitney10 Lea-Ann Kirkham11,12 Raquel Sá-Leão13 Jorge Vidal14 Hamish
Graham15,16 David Murdoch17 Glaucia Paranhos- Baccala18,19 David
Goldblatt20 William S. Pomat21 Emma Best22,23 Peter McIntyre24 Jodie
McVernon25,26 Daniel Weinberger27 Eileen Dunne2 J. Anthony Scott4 Allan W.
Cripps28 Grant Mackenzie3,29,30,31, Shabir Madhi32 Paul Torzillo34 Steve
Graham35 Cissy Kartasasmita36 Juliet O. Awori4,37 Amber Smith38 Markus Hilty
39 Chris Blyth 12,40,41 Tamara Pilishvili 42 Laura Hammitt43 Ross Andrews6,44
Kristy Crooks6,45 William P. Hanage46, Odilia Wijburg 5 Susan Morpeth47 Neil
French48 Allen Cheng49,50 Claudia Trappetti51 Elaine Tuomanen52 Jason
Rosch53 Narendra Arora54 Gail Rodgers55 Lay Myint Yoshida56 Peter
Richmond12,57,58 Paul Licciardi2,3 and Daniela M. Ferreira48
Affiliations
1NIHR Global Health Research Unit on Mucosal Pathogens, Division of
Infection and Immunity, University College London, London, UK
2Murdoch Children's Research Institute, Parkville, VIC Australia
3Department of Paediatrics, The University of Melbourne, Parkville, VIC
Australia
4London School of Hygiene and Tropical Medicine, London WC1H, UK
5Department of Microbiology and Immunology, The University of Melbourne
at the Peter Doherty Institute for Infection and Immunity, Melbourne,
Victoria, Australia
6Menzies School of Health Research, Charles Darwin University, Darwin,
Northern Territory 0810 Australia
7School of Medicine, Griffith University, Gold Coast, Australia
8Nuffield Department of Medicine, University of Oxford, Oxford, UK
9Department of Medicine, Imperial College London, London, UK
10Whitney Public Health Consulting LLC, Atlanta, Georgia, USA
11Centre for Child Health Research, The University of Western Australia, Perth,
Western Australia, Australia
12Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids
Institute, Perth, WA, Australia
13Instituto de Tecnologia Química e Biológica António Xavier, Universidade
Nova de Lisboa, Oeiras, Portugal
14Hubert Department of Global Health, Rollins School of Public Health,
Emory University, Atlanta, Georgia, USA
15Melbourne Children’s Global Health, University of Melbourne, MCRI, Royal
Children’s Hospital Melbourne, Australia
16Department of Paediatrics, University College Hospital Ibadan, Oyo state,
Nigeria
17Department of Pathology, University of Otago, Christchurch, New Zealand
18Center of Excellence for Tropical Infectious Diseases, Medical Diagnostic
Discovery Department (MD3) bioMérieux, Rio de Janeiro, Brazil
19Tropical Medicine Institute - University of São Paulo,São Paulo, Brazil
20UCL Great Ormond Street Institute of Child Health, 30 Guilford Street,
London WC1N 1EH, UK
21Papua New Guinea Institute of Medical Research, Homate Street, Goroka,
Eastern Highlands Province, Papua New Guinea
22Starship Hospital, Auckland 1023, New Zealand
23School of Medicine, University of Auckland, Auckland 1023, New Zealand
24National Centre for Immunisation Research and Surveillance, Kids Research,
Sydney Children’s Hospital Network and University of Sydney, Sydney, NSW,
Australia
25Victorian Infectious Diseases Reference Laboratory, Peter Doherty Institute
for Infection and Immunity, The Royal Melbourne Hospital and The
University of Melbourne, Melbourne, Victoria, Australia
26Melbourne School of Population and Global Health, The University of
Melbourne, Melbourne, Victoria
27Department of Epidemiology of Microbial Diseases, Yale School of Public
Health, New Haven, Connecticut, USA
28School of Medicine and Menzies Health Institute Queensland, Griffith
University, Griffith, Queensland, Australia
29Medical Research Council Unit, The Gambia at London School of Hygiene
& Tropical Medicine, London, UK
30Department of Disease Control, Faculty of Infectious and Tropical Diseases,
London School of Hygiene & Tropical Medicine, London, UK
31Institut de Recherche en Sante, de Surveillance Epidemiologique et de
Formation, Dakar, Senegal
32Medical Research Council, Respiratory and Meningeal Pathogens Research
Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg,
South Africa
33Department of Science/National Research Foundation: Vaccine Preventable
Diseases, Faculty of Health Sciences, University of Witwatersrand,
Johannesburg, South Africa
34Royal Prince Alfred Hospital, Sydney, New South Wales Australia
35Centre for International Child Health, University of Melbourne, Royal
Children’s Hospital, Murdoch Children’s Research Institute, Melbourne,
Victoria, Australia
36Department of Child Health, Universitas Padjadjaran/Hasan Sadikin General
Hospital, Bandung, West Java Indonesia
37Kenya Medical Research Institute - Wellcome Trust Research Programme,
Kilifi, Kenya
38Department of Pediatrics, University of Tennessee Health Science Center,
Memphis, TN 38163 USA
39Institute for Infectious Diseases, University of Bern, Bern, Switzerland
40School of Paediatrics and Child Health, University of Western Australia,
Perth, WA, Australia
41Princess Margaret Hospital for Children, Subiaco, Perth, WA, Australia
42Respiratory Diseases Branch, Division of Bacterial Diseases, National Center
for Immunization and Respiratory Diseases, Centers for Disease Control and
Prevention, U.S. Department of Health and Human Services, Atlanta, 30333,
Georgia, USA
43Center for American Indian Health, Johns Hopkins Bloomberg School of
Public Health, Baltimore, Maryland, USA
44National Centre for Epidemiology and Population Health, Australian
National University, Canberra, Australian Capital Territory Australia
45Hunter New England Local Health District, Population Health, Wallsend,
NSW, Australia
46Center for Communicable Disease Dynamics, Department of Epidemiology,
Harvard TH Chan School of Public Health, Boston, USA
47Middlemore Hospital, Counties Manukau District Health Board, Auckland,
New Zealand
48Liverpool School of Tropical medicine, Respiratory Infection Group,
Liverpool, Great Britain and Northern Ireland, UK
49Department of Infectious Diseases, Alfred Health, Melbourne, 3004,
Australia
50School of Public Health and Preventive Medicine, Monash University,
Melbourne, 3800, Australia
51Research Centre for Infectious Diseases, School of Biological Sciences,
University of Adelaide, Adelaide, SA, Australia
52Department of Infectious Diseases, St. Jude Children’s Research Hospital,
Memphis, TN 38105, USA
53Department of Infectious Diseases, St. Jude Children’s Research Hospital,
Memphis, TN 38105, USA
54National Certification Committee for Polio Eradication, New Delhi, India
55Bill & Melinda Gates Foundation, Seattle, WA, USA
56Department of Pediatric Infectious Diseases, Institute of Tropical Medicine,
Nagasaki University, 1-12-4 Sakamoto, Nagasaki, Japan
57School of Medicine, University of Western Australia, Perth 6009, Australia
58Department of General Paediatrics, Perth Children’s Hospital, Perth 6009,
Australia
Kwambana-Adams et al. Pneumonia            (2020) 12:2 Page 10 of 14
Authors’ contributions
CS, KM and BAKA conceptualized the report. The ISPPD Group contributed
to drafting different sections of the report, reviewed and approved the final
draft. BAKA, KM, and CS edited, compiled and approved the final version of
the report.
Funding
We are grateful to the ISPPD-11 major sponsors: The Bill & Melinda Gates
Foundation, Pneumonia, GlaxoSmithKline (GSK), Pfizer and MSD. We also
thank the general sponsors: PATH, Serum Institute of India as well as spon-
sors IVAC, LimmaTech Biologicals, City of Melbourne, Melbourne and Con-
vention Bureau.
Availability of data and materials
All the symposium sessions and abstracts can be accessed at https://isppd.
kenes.com/2018
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors confirm that they do not have any competing interest.
Author details
1NIHR Global Health Research Unit on Mucosal Pathogens, Division of
Infection and Immunity, University College London, London, UK. 2Murdoch
Children’s Research Institute, Parkville, VIC, Australia. 3Department of
Paediatrics, The University of Melbourne, Parkville, VIC, Australia. 4London
School of Hygiene and Tropical Medicine, London WC1H, UK. 5Department
of Microbiology and Immunology, The University of Melbourne at the Peter
Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Received: 10 June 2019 Accepted: 6 December 2019
References
1. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al.
Burden of disease caused by Streptococcus pneumoniae in children younger
than 5 years: global estimates. Lancet. 2009;374(9693):893–902.
2. Mackenzie GA, Hill PC, Jeffries DJ, Hossain I, Uchendu U, Ameh D, et al.
Effect of the introduction of pneumococcal conjugate vaccination on
invasive pneumococcal disease in the Gambia: a population-based
surveillance study. Lancet Infect Dis. 2016.
3. von Gottberg A, de Gouveia L, Tempia S, Quan V, Meiring S, von Mollendorf
C, et al. Effects of vaccination on invasive pneumococcal disease in South
Africa. N Engl J Med. 2014;371(20):1889–99.
4. Flasche S, Van Hoek AJ, Sheasby E, Waight P, Andrews N, Sheppard C, et al.
Effect of pneumococcal conjugate vaccination on serotype-specific carriage
and invasive disease in England: a cross-sectional study. PLoS Med. 2011;
8(4):e1001017.
5. Estimated Hib and pneumococcal deaths for children under 5 years of age,
2000 http://www.who.int/immunization/monitoring_surveillance/burden/
estimates/Pneumo_hib_2000/en/: World Health Organization; 2008 [.
6. International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg
School of Public Health. VIEW-hub Global Vaccine Introduction and
Implementation Report.
7. Wahl B, O'Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, et al. Burden
of Streptococcus pneumoniae and Haemophilus influenzae type b disease in
children in the era of conjugate vaccines: global, regional, and national
estimates for 2000-15. Lancet Glob Health. 2018;6(7):E744–E57.
8. Collaborators GM. Global, regional, and national under-5 mortality, adult
mortality, age-specific mortality, and life expectancy, 1970–2016: a
systematic analysis for the Global Burden of Disease Study 2016. Lancet.
2017;390(10106):E38–E.
9. Lewnard J, Givon-Lavi N, Dagan R. Early-life infection exacerbates
susceptibility to otitis media. Melbourne: 11th International Symposium on
Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
10. Binks M, Beissbarth J, Pizzutto S, Smith-Vaughan H, Andrews R, Leach A,
et al. Impact of pneumococal conjugate vaccination on childhood acute
lower respiratory infection in the Northern Territory of Australia: a decade of
data (1996–2015). Melbourne: 11th International Symposium on
Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
11. Agweyu A, Lilford R, English M. Clinical risk factors for mortality among
children classified as non-severe pneumonia under revised World Health
Organization (WHO) guidance. Melbourne: 11th International Symposium
on Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
12. WHO. Pneumococcal Disease https://www.who.int/ith/vaccines/
pneumococcal/en/2018 [Available from: https://www.who.int/ith/vaccines/
pneumococcal/en/.
13. Whitney CG, Goldblatt D, O'Brien KL. Dosing schedules for pneumococcal
conjugate vaccine: considerations for policy makers. Pediatr Infect Dis J.
2014;33(Suppl 2):S172–81.
14. Gurung M, Kandasamy R, Thorson S, Shrestha S, Ansari I, Shah G, et al. A
non-inferiority trial, comparing two-dose priming with the 10-valent
pneumococcal conjugate vaccine at 6 and 10 weeks with 6 and 14 weeks
in Nepali children. Melbourne: 11th International Symposium on
Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
15. Licciardi PV, Phan T, Toh ZQ, Balloch A, Hong NVP, Trung KV, et al.
Immunogenicity and memory B cell response post-booster and at 8
months of age following alternative pneumococcal vaccination strategies in
Vietnam. Melbourne: 11th International Symposium on Pneumococci and
Pneumococcal Diseases (ISPPD-11); 2018.
16. Bar-Zeev N, Swarthout T, Alaerts M, Samson PW, Brown C, Phiri JC, et al.
Direct and indirect impact of 13v-pneumococcal conjugate vaccine on
invasive pneumococcal disease in Blantyre, Malawi. Melbourne: 11th
International Symposium on Pneumococci and Pneumococcal Diseases
(ISPPD-11); 2018.
17. Tagbo B, Rowan B, Fajolu I, AbdulKadir M, Bashir M, Okunola P, et al.
Paediatric bacterial meningitis surveillance in Nigeria from 2010 to 2016.
Melbourne: 11th International Symposium on Pneumococci and
Pneumococcal Diseases (ISPPD-11); 2018.
18. Yang J, Siddiqui S, Uslu K, Ireland D, Windy A, Verthelyi D, et al.
Characterization of pathways responsible for the weak immune response in
newborns immunized with conjugate polysaccharide vaccines. Melbourne:
11th International Symposium on Pneumococci and Pneumococcal
Diseases (ISPPD-11); 2018.
19. Campbell H, Gupta S, Dolan GP, Kapadia SJ, Kumar Singh A, Andrews N,
et al. Review of vaccination in pregnancy to prevent pertussis in early
infancy. J Med Microbiol. 2018;67(10):1426–56.
20. Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O'Brien KL, Team
AAPBS, et al. Estimating the burden of pneumococcal pneumonia among
adults: a systematic review and meta-analysis of diagnostic techniques.
PLoS One. 2013;8(4):e60273.
21. Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, et al.
Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide
vaccine against pneumococcal pneumonia in adults aged 65 years or older:
a multicentre, prospective, test-negative design study. Lancet Infect Dis.
2017;17(3):313–21.
22. Falkenhorst G, Remschmidt C, Harder T, Hummers-Pradier E, Wichmann O,
Bogdan C. Effectiveness of the 23-valent pneumococcal polysaccharide
vaccine (PPV23) against pneumococcal disease in the elderly: systematic
review and meta-analysis. PLoS One. 2017;12(1):e0169368.
23. Naito T, Yokokawa H, Watanabe A. Impact of the national routine
vaccination program on 23-valent pneumococcal polysaccharide vaccine
vaccination rates in elderly persons in Japan. J Infect Chemother. 2018;24(6):
496–8.
24. Suzuki M. Pneumonia in the elderly in Asia – a coming tsunami. Melbourne:
11th International Symposium on Pneumococci and Pneumococcal
Diseases (ISPPD-11); 2018.
25. MacIntyre R, Ridda I, Rahman B, Chughtai A, Moa A, Jones T. Long
term follow-up study to examine the immunogenicity of 7-valent
pneumococcal conjugate vaccine (PCV7) compared to 23-valent
polysaccharide vaccine (23vPPV) in frail, hospitalized elderly. Melbourne:
11th International Symposium on Pneumococci and Pneumococcal
Diseases (ISPPD-11); 2018.
26. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al.
Polysaccharide conjugate vaccine against pneumococcal pneumonia in
adults. N Engl J Med. 2015;372(12):1114–25.
Kwambana-Adams et al. Pneumonia            (2020) 12:2 Page 11 of 14
27. Gessner B, Jiang Q, Werkhoven CHV, Sings H, Webber C, Scott D, et al. A
public health evaluation of 13-valent pneumococcal conjugate vaccine
impact on adult disease outcomes from a randomized clinical trial in the
Netherlands. Melbourne: 11th International Symposium on Pneumococci
and Pneumococcal Diseases (ISPPD-11); 2018.
28. Thorrington D, van Rossum L, Knol M, de Melker H, Rumke H, Hak E, et al.
Impact and cost-effectiveness of different vaccination strategies to reduce
the burden of pneumococcal disease among elderly in the Netherlands.
PLoS One. 2018;13(2):e0192640.
29. O'Leary ST, Maldonado YA, Kimberlin DW. Update from the advisory
committee on immunization practices. J Pediatric Infect Dis Soc. 2019.
30. Scott A. The preventable burden of pneumonia among adults in Africa.
Melbourne: 11th International Symposium on Pneumococci and
Pneumococcal Diseases (ISPPD-11); 2018.
31. Av G, Kleynhans J, Ld G, Tempia S, Meiring S, Quan V, et al. Trends in
invasive pneumococcal disease among adults aged ≥25 years, South Africa,
2005–2016. Melbourne: 11th International Symposium on Pneumococci and
Pneumococcal Diseases (ISPPD-11); 2018.
32. Ludwig E, Bonanni P, Rohde G, Sayiner A, Torres A. The remaining challenges
of pneumococcal disease in adults. Eur Respir Rev. 2012;21(123):57–65.
33. Jayasinghe S, Chiu C, Pennington K, Krause V, Hood J, Blyth C. Rising
disparity: an increasing burden of invasive pneumococcal disease in
Australian Aboriginals (2002–2014). Melbourne: 11th International
Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
34. Weatherholtz R, Grant L, Douglass G, Tso C, Reid R, Rudolph K, et al. Impact
of pneumococcal conjugate vaccines (PCV) on invasive pneumococcal
disease among American Indians living on the Navajo Reservation.
Melbourne: 11th International Symposium on Pneumococci and
Pneumococcal Diseases (ISPPD-11); 2018.
35. Hammitt L. Requirements to make the switch for alternative dose vaccine
schedules among indigenous peoples. Melbourne:: 11th International
Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
36. Kong K. Impact of PCVs on the burden of otitis in first nations populations.
Melbourne: 11th International Symposium on Pneumococci and
Pneumococcal Diseases (ISPPD-11); 2018.
37. Rull M, Masson S, Peyraud N, Simonelli M, Ventura A, Dorion C, et al. The
new WHO decision-making framework on vaccine use in acute
humanitarian emergencies: MSF experience in Minkaman. South Sudan
Confl Health. 2018;12:11.
38. Dawood FS, Ambrose JF, Russell BP, Hawksworth AW, Winchell JM, Glass N,
et al. Outbreak of pneumonia in the setting of fatal pneumococcal
meningitis among US Army trainees: potential role of chlamydia
pneumoniae infection. BMC Infect Dis. 2011;11:157.
39. DeMaria A Jr, Browne K, Berk SL, Sherwood EJ, McCabe WR. An outbreak of type
1 pneumococcal pneumonia in a men's shelter. Jama. 1980;244(13):1446–9.
40. Nuorti JP, Butler JC, Crutcher JM, Guevara R, Welch D, Holder P, et al. An outbreak
of multidrug-resistant pneumococcal pneumonia and bacteremia among
unvaccinated nursing home residents. N Engl J Med. 1998;338(26):1861–8.
41. Tan CG, Ostrawski S, Bresnitz EA. A preventable outbreak of pneumococcal
pneumonia among unvaccinated nursing home residents in New Jersey
during 2001. Infect Control Hosp Epidemiol. 2003;24(11):848–52.
42. Mercat A, Nguyen J, Dautzenberg B. An outbreak of pneumococcal
pneumonia in two men's shelters. Chest. 1991;99(1):147–51.
43. WHO. Accessing Affordable and Timely Supply of Vaccines for use in
Humanitarian Emergencies: the Humanitarian Mechanism. https://www.
who.int/immunization/programmes_systems/sustainability/The_
Humanitarian_Mechanism_ToRs.pdf?ua=1: World Health Organisation; 2017.
44. Checchi F, Margini F. Preventing pneumococcal disease in displaced
populations. Melbourne: 11th International Symposium on Pneumococci
and Pneumococcal Diseases (ISPPD-11); 2018.
45. Gargano LM, Hajjeh R, Cookson ST. Pneumonia prevention: cost-
effectiveness analyses of two vaccines among refugee children aged under
two years, Haemophilus influenzae type b-containing and pneumococcal
conjugate vaccines, during a humanitarian emergency, Yida camp, South
Sudan. Vaccine. 2017;35(3):435–42.
46. Kwambana-Adams B. Outbreaks of pneumococcal meningitis in Africa.
Melbourne: 11th International Symposium on Pneumococci and
Pneumococcal Diseases (ISPPD-11); 2018.
47. Lessa FC, Spiller MT, Soda E, Weinberger D, Griffin MR, Grijalva CG, et al
Impact of introduction of infant vaccination with 13-valent pneumococcal
conjugate vaccine (PCV13) on pneumonia and invasive pneumococcal
disease (IPD) hospitalizations in the United States, 2005–2014. Melbourne:
11th International Symposium on Pneumococci and Pneumococcal
Diseases (ISPPD-11); 2018.
48. Ebruke C, Roca A, Egere U, Darboe O, Hill PC, Greenwood B, et al. Temporal
changes in nasopharyngeal carriage of Streptococcus pneumoniae serotype
1 genotypes in healthy Gambians before and after the 7-valent
pneumococcal conjugate vaccine. PeerJ. 2015;3:e903.
49. Kellner J, Ricketson L, Vanderkooi O, Pyra S, Tyrell G, Demczuk W, et al.
Whole genome phylogenetic analysis of Streptococcus pneumoniae causing
an outbreak of serotype 4 invasive pneumococcal disease outbreak in
Alberta, Canada. Melbourne: 11th International Symposium on
Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
50. Kwambana-Adams BA, Asiedu-Bekoe F, Sarkodie B, Afreh OK, Kuma GK,
Owusu-Okyere G, et al. An outbreak of pneumococcal meningitis among
older children (>/=5 years) and adults after the implementation of an infant
vaccination programme with the 13-valent pneumococcal conjugate
vaccine in Ghana. BMC Infect Dis. 2016;16(1):575.
51. Khadka B, Amatya P, Carter MJ, Park K, Smedley M, Thorson S, et al.
Comparision of WHO pneumonia case definition and radiology for the
diagnosis of pneumonia in children at Patan hospital Nepal. Melbourne:
11th International Symposium on Pneumococci and Pneumococcal
Diseases (ISPPD-11); 2018.
52. Mahomed N, Philipsen R, Melendez J, Ginneken BV, Groome M, Madhi SA.
Computer Aided Diagnosis for WHO Standardized Chest X-Ray
Interpretation in Children, Phase 2. Melbourne: 11th International
Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
53. Boyd N, King C, Walker I, Zadutsa B, Bernstein M, Ahmed S, et al. Human
centered design usability testing of a reusable universal pediatric pulse
oximeter probe developed for children <5 years old in low-resource
settings (LRS). Melbourne: 11th International Symposium on Pneumococci
and Pneumococcal Diseases (ISPPD-11); 2018.
54. Kakiuchi S, Suzuki M, Doubhadel BG, Ishifuji T, Asoh N, Ariyoshi K, et al.
Detection and serotyping of pneumococci in adult pneumonia patients:
Comparison of high-throughput real-time PCR assay using sputum
specimens and multiplex urinary antigen detection assay. Melbourne: 11th
International Symposium on Pneumococci and Pneumococcal Diseases
(ISPPD-11); 2018.
55. Lim W-S. Epidemiology of pneumococcal pneumonia in adults in the post-
PCV era. Melbourne: 11th International Symposium on Pneumococci and
Pneumococcal Diseases (ISPPD-11); 2018.
56. Bassat Q. Minimally invasive tissue sampling to better define cause of
pneumonia death. Melbourne: 11th International Symposium on
Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
57. Sabharwal V, Yang R, Kohane D, Pelton S. Efficacy of transtympanic
gemifloxacin and ciprofloxacin gel formulation against experimental otitis
media in a chinchilla model due to Streptococcus pneumoniae. Melbourne:
11th International Symposium on Pneumococci and Pneumococcal
Diseases (ISPPD-11); 2018.
58. Hausdorff WP, Hanage WP. Interim results of an ecological experiment -
conjugate vaccination against the pneumococcus and serotype
replacement. Hum Vaccin Immunother. 2016;12(2):358–74.
59. Pilishvili T, Gierke R, Farley M, Schaffner W, Thomas A, Reingold A, et al.
Changes in invasive pneumococcal disease (IPD) among children following
6 years of 13-valent pneumococcal conjugate vaccine (PCV13) use in the
United States. 11th International Symposium on Pneumococci and
Pneumococcal Diseases (ISPPD-11). Melbourne; 2018.
60. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM,
et al. Effect of use of 13-valent pneumococcal conjugate vaccine in
children on invasive pneumococcal disease in children and adults in
the USA: analysis of multisite, population-based surveillance. Lancet
Infect Dis. 2015;15(3):301–9.
61. Savulescu C, Colzani E, Pastore-Celentano L, Hanquet G, group S. Impact of
higher-valency pneumococcal conjugate vaccines on invasive
pneumococcal disease in children under 5 years (2011–2016): SpIDnet– a
European multicentre study. Melbourne: 11th International Symposium on
Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
62. Ladhani S, Collins S, Djennad A, Sheppard C, Borrow R, Fry N, et al. Rapid
increase in non-vaccine serotypes causing invasive pneumococcal disease
in England and Wales: a prospective national observational cohort study,
2000–2017. Melbourne: 11th International Symposium on Pneumococci and
Pneumococcal Diseases (ISPPD-11); 2018.
Kwambana-Adams et al. Pneumonia            (2020) 12:2 Page 12 of 14
63. Lewnard JA, Hanage WP. Making sense of differences in pneumococcal
serotype replacement. Lancet Infect Dis. 2019.
64. Senghore M, Kwambana-Adams B, Worwui A, Teintcheu PE, Salaudeen R, Av
G, et al. Evolution of pneumococci causing invasive disease in the Gambia
before and after the introduction of pneumococcal conjugate vaccines.
Melbourne: 11th International Symposium on Pneumococci and
Pneumococcal Diseases (ISPPD-11); 2018.
65. Mungall B, Soumahoro L, Hoet B. Correlating PCV impact on carriage with
impact on disease: a systematic review. Melbourne: 11th International
Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
66. Tuivaga E, Reyburn R, Nguyen C, Ratu T, Nand D, Kado J, et al. Temporal
association of 10-valent pneumococcal conjugate vaccine introduction with
all-cause, severe, hypoxic and radiological pneumonia hospitalisations in
children and elderly in Fiji: a time-series analysis. Melbourne: 11th International
Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
67. Shrestha S, Thorson S, Gurung M, Carter MJ, Kandasamy R, Garcia C, et al. A
comprehensive pneumococcal vaccine impact assessment in Nepal.
Melbourne: 11th International Symposium on Pneumococci and
Pneumococcal Diseases (ISPPD-11); 2018.
68. Ravikumar KL, Govindan V, Nagaraj G. What is happening with PCV
introduction in India?. Melbourne: 11th international Symposium on
Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
69. Chan J, Mollendorf CV, Dunne E, Fox K, Hinds J, Vincente SL, et al. Using
nasopharyngeal carriage surveillance in children hospitalised with
pneumonia to determine the pneumococcal conjugate vaccine coverage
required for indirect immunity in Mongolia. Melbourne: 11th International
Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
70. Croucher N, Corander J, Colijn C. Optimising vaccine formulations to minimise
disease and antibiotic treatment failures. Melbourne: 11th International
Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
71. Ojal J, Griffiths U, Hammitt LL, Adetifa I, Akec D, Tabu C, et al. The merits of
sustaining pneumococcal vaccination after transitioning from GAVI support
– a cost-effectiveness study for Kenya. Melbourne: 11th International
Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
72. Sbarra AN, Shioda K, Warren JL, Oliveira LHD, Weinberger DM. Improving
credibility of PCV impact estimates using pooled analysis. Melbourne: 11th
International Symposium on Pneumococci and Pneumococcal diseases
(ISPPD-11); 2018.
73. Choi YH, Miller E. Modelling the impact of changing from a 2+1 to 1+1
PCV13 schedule in England and Wales. Melbourne: 11th International
Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
74. Rupp R, Johnston W, Hurley D, Petrecz M, Li J, Nolan K, et al. A dose
ranging study of 15-valent pneumococcal conjugate vaccine (PCV-15) in
healthy infants. Melbourne: 11th International Symposium on Pneumococci
and Pneumococcal Diseases (ISPPD-11); 2018.
75. Skinner J, Kaufhold R, McGuinness D, McHugh P, Winters M, Smith W, et al.
Immunogenicity of PCV24, a next generation pneumococcal conjugate
vaccine, in Macaques. Melbourne: 11th International Symposium on
Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
76. Lalwani S, Bavdekar A, Ramanan PV, Dhere R, Sethna V. Safety and
immunogenicity of a 10-valent pneumococcal conjugate vaccine in healthy
PCV-naïve Indian toddlers – a phase 2 double-blind randomized controlled
trial. Melbourne: 11th International Symposium on Pneumococci and
Pneumococcal Diseases (ISPPD-11); 2018.
77. Stacey H, Rosen J, Peterson J, Williams-Diaz A, Gakhar V, Sterling T, et al.
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine
(PCV-15) compared to PCV-13 in healthy older adults. Melbourne: 11th
International Symposium on Pneumococci and Pneumococcal Diseases
(ISPPD-11); 2018.
78. Goulart C, Rodriguez D, Kanno AI, Lu YJ, Malley R, Leite LC. Recombinant
BCG expressing a PspA-PdT fusion protein protects mice against
pneumococcal lethal challenge in a prime-boost strategy. Vaccine. 2017;
35(13):1683–91.
79. Ren B, Li J, Genschmer K, Hollingshead SK, Briles DE. The absence of PspA
or presence of antibody to PspA facilitates the complement-dependent
phagocytosis of pneumococci in vitro. Clin Vaccine Immunol. 2012;19(10):
1574–82.
80. Khan MN, Sharma SK, Filkins LM, Pichichero ME. PcpA of Streptococcus
pneumoniae mediates adherence to nasopharyngeal and lung epithelial
cells and elicits functional antibodies in humans. Microbes Infect. 2012;
14(12):1102–10.
81. Bologa M, Kamtchoua T, Hopfer R, Sheng X, Hicks B, Bixler G, et al. Safety and
immunogenicity of pneumococcal protein vaccine candidates: monovalent
choline-binding protein a (PcpA) vaccine and bivalent PcpA–pneumococcal
histidine triad protein D vaccine. Vaccine. 2012;30(52):7461–8.
82. Rahman T, Thornton R, Corscadden K, Granland C, Francis J, Solomon V,
et al. Antibody titres against pneumococcal protein vaccine antigens in
Papua New Guinean children at high risk of pneumococcal disease.
Melbourne: 11th International Symposium on Pneumococci and
Pneumococcal Diseases (ISPPD-11); 2018.
83. Novick S, Shagan M, Blau K, Lifshitz S, Givon-Lavi N, Grossman N, et al.
Adhesion and invasion of Streptococcus pneumoniae to primary and
secondary respiratory epithelial cells. Mol Med Rep. 2017;15(1):65–74.
84. Vernatter J, Pirofski LA. Current concepts in host-microbe interaction leading
to pneumococcal pneumonia. Curr Opin Infect Dis. 2013;26(3):277–83.
85. Aprianto R, Slager J, Holsappel S, Veening JW. Time-resolved dual RNA-seq
reveals extensive rewiring of lung epithelial and pneumococcal
transcriptomes during early infection. Genome Biol. 2016;17(1):198.
86. Jhelum H, Sori H, Sehgal D. A novel extracellular vesicle-associated
endodeoxyribonuclease helps Streptococcus pneumoniae evade neutrophil
extracellular traps and is required for full virulence. Sci Rep. 2018;8(1):7985.
87. Panagiotou S, Khandaker S, Chaguza C, Yangl M, Kadioglu A. Further
understanding of pathogenesis and host immunity in pneumococcal
meningitis. Melbourne: 11th International Symposium on Pneumococci and
Pneumococcal Diseases (ISPPD-11); 2018
88. Iovino F, Engelen-Lee JY, Brouwer M, van de Beek D, van der Ende A, Valls
Seron M, et al. pIgR and PECAM-1 bind to pneumococcal adhesins RrgA and
PspC mediating bacterial brain invasion. J Exp Med. 2017;214(6):1619–30.
89. Iovino F, Thorsdottir S, Henriques-Normark B. Receptor Blockade: A Novel
Approach to Protect the Brain From Pneumococcal Invasion. J Infect Dis. 2018.
90. Campo JJ, Turner P, Le TQ, Liang X, Croucher NJ, Goldblatt D. Proteomic
antibody profiles during the first two years of life in infants on the Thailand-
Myanmar border. Melbourne: 11th International Symposium on
Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
91. Croucher N, Le T, Pablo J, Hung C, Teng A, Tate A, et al. Panproteome-wide
view of the immunological response to a whole cell pneumococcal vaccine.
Melbourne: 11th International Symposium on Pneumococci and
Pneumococcal Diseases (ISPPD-11); 2018.
92. Mitsi E, Carniel B, Jochems SP, Rylance J, Reine J, Schanoski AS, et al. Cross-
talk of alveolar macrophages and T-cells boosts the lung immunity post
nasopharyngeal pneumococcal colonisation. Melbourne: 11th International
Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
93. Abudulai L, Fernandez S, Corscadden K, Kirkham LA, Hunter M, Post JJ, et al.
Production of IgG2 antibodies to pneumococcal polysaccharides requires
ICOS+ circulating memory follicular helper T-cells and is impaired by HIV-1
infection. Melbourne: 11th International Symposium on Pneumococci and
Pneumococcal Diseases (ISPPD-11); 2018.
94. Makenga G, Mtove G, Yin K, Booy R. Immune response to pneumococcal
conjugate vaccine (PCV13) serotypes in Tanzanian children with HIV/AIDS.
Melbourne: 11th International Symposium on Pneumococci and
Pneumococcal Diseases (ISPPD-11); 2018.
95. Apiwattanakul N, Thomas PG, Kuhn RE, Herbert DR, McCullers JA. Helminth
infections predispose mice to pneumococcal pneumonia but not to other
pneumonic pathogens. Med Microbiol Immunol. 2014;203(5):357–64.
96. McCullers JA. The co-pathogenesis of influenza viruses with bacteria in the
lung. Nat Rev Microbiol. 2014;12(4):252–62.
97. Toizumi M, Nguyen HA, Iwasaki C, Vo MH, Takegata M, Kitamura N, et al.
Streptococcus pneumoniae interacts with respiratory syncytial virus and
increases severity of respiratory illness among Vietnamese children.
Melbourne: 11th International Symposium on Pneumococci and
Pneumococcal Diseases (ISPPD-11); 2018.
98. Khandaker S, Yang M, Kadioglu A. Effect of respiratory syncytial virus
infection on pneumococcal colonisation and invasive disease. Melbourne:
11th International Symposium on Pneumococci and Pneumococcal
Diseases (ISPPD-11); 2018.
99. Law A, Shears R, Grencis R, Kadioglu A, Neill D. Low dose Trichuris muris
infection impairs host immune control of Streptococcus pneumoniae
nasopharyngeal carriage. Melbourne: 11th International Symposium on
Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
100. Smith AM, Adler FR, Ribeiro RM, Gutenkunst RN, McAuley JL, McCullers JA,
et al. Kinetics of coinfection with influenza A virus and Streptococcus
pneumoniae. Plos Pathog. 2013;9(3).
Kwambana-Adams et al. Pneumonia            (2020) 12:2 Page 13 of 14
101. Ghoneim HE, McCullers JA. Adjunctive corticosteroid therapy improves lung
immunopathology and survival during severe secondary pneumococcal
pneumonia in mice. J Infect Dis. 2014;209(9):1459–68.
102. Califano D, Furuya Y, Metzger DW. Effects of influenza on alveolar
macrophage viability are dependent on mouse genetic strain. J Immunol.
2018;201(1):134–44.
103. Lewnard J, Givon-Lavi N, Dagan R. Pneumococcal serotype-specific
interaction with non-typeable Haemophilus influenzae (NTHI) is consistent in
acute bacterial conjunctivitis and otitis media. Melbourne: 11th International
Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
104. Hiller L. Genomics plasticity: tissue tropism, gene regulation and strain-strain
interactions. Melbourne: 11th International Symposium on Pneumococci
and Pneumococcal Diseases (ISPPD-11); 2018.
105. Lehtinen S. The role of duration of carriage in the dynamics of drug and
multi-drug resistance. Melbourne: 11th International Symposium on
Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
106. Gladstone R, Md P, Wolter N, Madhi S, Nzenze S, Lo S, et al. Beyond
serotype: the contribution of genotype to invasiveness. Melbourne: 11th
International Symposium on Pneumococci and Pneumococcal Diseases
(ISPPD-11); 2018.
107. Ebruke C, Senghore M, Worwui A, Tientcheu PE, Okoi C, Salaudeen R, et al.
Comparative genomic analysis of Streptococcus pneumoniae Serotype 1
strains from West Africa (1996–2016). Melbourne: 11th International
Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
108. Lees J, Ferwerda B, Kremer P, Wheeler N, Mercedes VS, Croucher N, et al.
Joint sequencing of host and pathogen genomes reveals the genetics
underlying susceptibility to and severity of pneumococcal meningitis.
Melbourne: 11th International Symposium on Pneumococci and
Pneumococcal Diseases (ISPPD-11); 2018.
109. Satzke C, Turner P, Virolainen-Julkunen A, Adrian PV, Antonio M, Hare KM,
et al. Standard method for detecting upper respiratory carriage of
Streptococcus pneumoniae: updated recommendations from the World
Health Organization pneumococcal carriage working group. Vaccine. 2013;
32(1):165–79.
110. Manenzhe R, Moodley C, Dube FS, Wright M, Lennard K, Zar H, et al.
Shotgun sequencing to elucidate pneumococcal strain level
nasopharyngeal colonization patterns and antimicrobial resistance in a
South African birth cohort. Melbourne: 11th international symposium on
pneumococci and pneumococcal diseases (ISPPD-11).
111. Dube FS, BS D, Nduru P, Gladstone R, Zar HJ, Nicol MP. Characterisation of
lineage and locus-specific variations associated with pneumococcal carriage
dynamics post PCV-13 implementation in an African birth cohort: the
Drakenstein Child Health Study. Melbourne: 11th International Symposium
on Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
112. Dunne E, Murad C, Sudigdoadi S, Fadlyana E, Tarigan R, Pell C, et al.
Pneumococcal carriage dynamics during the first year of life: A longitudinal
study in Indonesian infants. Melbourne: 11th International Symposium on
Pneumococci and Pneumococcal Diseases (ISPPD-11); 2018.
113. Swarthout TD, Gori A, Bar-Zeev N, Everett D, Kamngona AW, Brown C, et al.
Pneumococcal serotyping of Malawi carriage samples by latex
agglutination, whole genome sequencing (PneumoCat) and DNA
microarray is highly concordant: “which should you choose?” Melbourne:
11th international symposium on pneumococci and pneumococcal diseases
(ISPPD-11); 2018.
114. Handem S, Tavares DA, Carvalho RJ, Hd L, Hinds J, Sá-Leão R. Identification
of Streptococcus pneumoniae by a real-time PCR assay targeting SP2020.
Melbourne: 11th International Symposium on Pneumococci and
Pneumococcal Diseases (ISPPD-11); 2018.
115. Lessa FC, Beall B, Milucky J, Rouphael N, Bennett NM, Talbot HK, et al.
Editors. Streptocccus mitis expressing pneumococcal serotype 1 capsule.
Melbourne: 11th international symposium on pneumococci and
pneumococcal diseases (ISPPD-11); 2018.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Kwambana-Adams et al. Pneumonia            (2020) 12:2 Page 14 of 14
